Tag Archives: Bristol Myers Squibb

HIV Market Banking on Fixed-Dose Treatments

By George Koroneos | Published: July 8, 2010
The HIV markets are expected to grow for the next two years, but major patent expirations in the following years will have a huge impact on pharmaceutical sales by 2019, according to a new report by DataMonitor. Antiretroviral sales in 2009 were estimated at $11.8 billion. While that figure is forecast to hit $14.4 billion in [...]
Posted in R&D | Also tagged , , , , , , | Leave a comment

Patient Adherence Awards Winners Revealed

By George Koroneos | Published: April 28, 2010
Image via Wikipedia The Center for Business Intelligence, on Monday, revealed winners of its annual Strategic Patient Adherence Awards as part of its two-day conference about patient compliance with their drug regiments. This year’s award winners are: Best Integrated Program—Shire Pharmaceuticals: FOSRENOL ON TRACK Direct To Patient Support Program Best Disease State Program—BMS/Sanofi-Aventis Canada & Rx Canada: My Plavix [...]
Posted in Events, Strategy | Also tagged , , , , , , , , | Leave a comment

AstraZeneca, BMS Announce Layoffs and Buyouts

By George Koroneos | Published: October 21, 2009
AstraZeneca was the topic of conversation this week as word broke that the company is offering buyout deals to every member of its 5,500 US sales force. “AstraZeneca is making changes to our sales force, which will be managed first by looking at vacancies and offering field sales employees the opportunity to self-identify whether they are [...]
Posted in Strategy | Also tagged , , , , , , , | 1 Comment

Judge Throws The Book At Former Bristol-Myers Squibb Exec

By Walter Armstrong | Published: June 9, 2009
Media wordsmiths are competing to outdo one another today in punny reporting on the news that ex-BMS exec Andrew Bodnar has been sentenced to write a book about the role he played in the firm’s 2006 reverse-payments case over generic Plavix. “Pen-ance: Bristol-Myers Exec Gets Two Years of Hard Writing,” The Wall Street Journal Law Blog [...]
Posted in Legal | Also tagged , , , , , , , | Leave a comment

Gilead Making a Bundle

By Walter Armstrong | Published: February 10, 2009
Gilead Sciences has once again proven that independent biotechs can innovate with the best of Big Pharma. The Silicon Valley company’s wizardry at weaving multiple drugs into a single weft enabled it to overthrow GlaxoSmithKline as king of HIV in 2007. Yesterday, at the 16th annual Congress of Retroviruses and Opportunistic Infections (CROI), the biotech [...]
Posted in Biotech, Emerging Markets, R&D | Also tagged , , | Leave a comment